Dr. Eva Hudgins Kerby, MD

Dr. Kerby practices at Columbia University Irving Medical Center in New York, New York.

Dr. Kerby's NPI, 1336526581, was assigned on April 27, 2015. Dr. Kerby graduated from Perelman School of Medicine - Philadelphia in 2015. Dr. Kerby holds New York license 299154.

Dr. Kerby's primary practice is Columbia University Irving Medical Center, at 622 W 168th St, New York, NY 10032 in New York County. The practice phone is (212) 305-4920.

Dr. Kerby's primary practice is Columbia University Irving Medical Center in New York, New York. Dr. Kerby is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is Weill Cornell Physicians. Dmand AI also links Dr. Kerby to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kerby practices, 2 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Kerby's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Kerby is board certified in dermatology by the American Board of Dermatology. Dr. Kerby is licensed in New York.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, cold sores or genital herpes, contact dermatitis, hives, itchy rashes and psoriasis among the conditions Dr. Kerby treats.

CMS data shows 1,254 Medicare services from Dr. Kerby across 15 procedure codes in 2024, for 467 Medicare patients. Medicare paid $83,943 for them. Every service was in an office.

CMS counts 467 Medicare patients who saw Dr. Kerby in 2024. The largest group is 65 to 74, with 206 patients. 75% of them have high cholesterol, and 64% have high blood pressure. 13% are also on Medicaid. Their average risk score is 1.09, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Kerby's median patient age at 47, with 72% women.

In 2024, Dr. Kerby wrote 1,091 Medicare Part D claims for 333 patients. 90% of them were for generic drugs. CMS names the drug for 917 of them, across 18 drugs with 11 or more claims each, at $350,819 in total drug cost. In 2023, CMS named 656 claims across 17 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Kerby for performance year 2024, reported through an alternative payment model (APM). Dr. Kerby accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kerby as offering telehealth. CMS counts 251 procedures of removal of skin lesions by Dr. Kerby, more than 81% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 4 papers to Dr. Kerby, published from 2017 to 2022. 2022 was the busiest year, with 2. Dr. Kerby has published most often in J Am Acad Dermatol. Dr. Kerby's most frequent co-authors are Nancy J. Bunin, MD, Shelby R. Lies, MD and Byron Lee Limmer, MD.

CMS Open Payments shows 15 general payments to Dr. Kerby from 8 drug and device companies from 2019 to 2025. Consulting fees make up the largest share, 72% of the total. Janssen Pharmaceuticals, Inc paid the most, $1,430.

Dr. Kerby graduated from Perelman School of Medicine - Philadelphia in 2015.

Dr. Kerby is in network with 16 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.